Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Share this content:
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Sponsor and Collaborators
Dana-Farber Cancer Institute

Contact
Toni K Choueiri, MD
617-632-5456
Toni_Choueiri@dfci.harvard.edu

Principal Investigator
Toni K Choueiri, MD
Dana-Farber Cancer Institute

ClinicalTrials.gov Identifier
NCT01283048
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters